Lynparza backed by CHMP for BRCA-mutated pancreatic cancer

1st June 2020 Uncategorised 0

Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ

More: Lynparza backed by CHMP for BRCA-mutated pancreatic cancer
Source: News